Goldenwell Biotech (GWLL) Equity Ratio (2019 - 2025)

Goldenwell Biotech has reported Equity Ratio for 7 years, with the latest figure at 0.43 in Q3 2025.

• For the quarter ending Q3 2025, Equity Ratio fell 501.24% year-over-year to 0.43; the trailing twelve-month figure through Sep 2025 stood at 0.43 (down 501.24% YoY), and the FY2024 full-year result was 0.21, down 156.73% from the prior year.
• Equity Ratio for Q3 2025 stood at 0.43, down from 0.35 in the prior quarter.
• The five-year high for Equity Ratio was 0.89 in Q3 2022, with the low at 0.43 in Q3 2025.
• Historically, Equity Ratio has averaged 0.41 across 5 years, with a median of 0.65 in 2021.
• Annual changes were most pronounced in 2022 — Equity Ratio surged 30.61% — and 2025, when it sank 1909.98%.
• Goldenwell Biotech's Equity Ratio stood at 0.65 in 2021, then advanced by 24.01% to 0.81 in 2022, then plunged by 54.24% to 0.37 in 2023, then slumped by 156.73% to 0.21 in 2024, then tumbled by 104.17% to 0.43 in 2025.
• The last three Equity Ratio figures came in at 0.43 (Q3 2025), 0.35 (Q2 2025), and 0.43 (Q1 2025), per Business Quant data.